<DOC>
	<DOC>NCT03067753</DOC>
	<brief_summary>Monosialoganglioside Ganglioside in Cerebral Radiation Necrosis</brief_summary>
	<brief_title>Monosialoganglioside Ganglioside in Cerebral Radiation Necrosis</brief_title>
	<detailed_description>A prospective phase II trial was conducted to test the efficacy of monosialoganglioside ganglioside for the treatment of cerebral radiation necrosis</detailed_description>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<criteria>Undergone only one course of definitive radiotherapy for histologically confirmed nasopharyngeal carcinoma years before; At least two consecutive MRI study supporting the diagnosis of cerebral radiation necrosis(CRN) with an interval of 34 months, with the second MRI showing progressive disease compared with the first MRI; Progressive neurologic symptoms or signs; Minimental status examination(MMSE) score must be ≤27; Karnofsky performance status≥70 ; Supposed to live more than 6 months. After the second course of radiotherapy for recurrent nasopharyngeal carcinoma; Local or regional relapse,or with distant metastasis; Cerebrovascular disease; Second primary malignancy; Diabetes.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>